RNAのアプリケーション - Stevanato Group
Stevanato Groupの統合ソリューションが、RNAテクノロジーがもたらす課題の軽減にどのように役立つかをご覧ください。
Home - Stevanato Group > Markets - Stevanato Group > RNAのアプリケーション - Stevanato Group
page-wrapper

RNA – 次世代テクノロジー

RNAベースのアプリケーションの使用は、バイアル (市場投入までの時間を短縮する必要がある) や充填済みシリンジ (PFS) (投与の正確性と使いやすさが要求される) の両方で増加しています。このため、サプライチェーンおよび冷蔵保管 (該当する場合)、またはライフサイクル管理中に、いくつかの技術的な考慮事項と課題が生じています。

RNA薬剤の特徴

RNAは、容器閉鎖システム内の粒子に対して高い感度を示す脂質ナノ粒子にカプセル化されています。これにより、医薬品メーカーが考慮しなければならない製造上の課題がいくつか生じます。

主な課題
403 Cold Temperature

低温貯蔵庫でのサプライチェーン中

164 Product Change Notification

ライフサイクル管理中

199A Biologic Molecule

医薬品の安定性の確保中

67 Chemical Analysis

さまざまな技術プラットフォームの統合と管理 (脂質ナノ粒子製剤など)

rna-based cta hero gated DK
rna-based cta hero gated DK

Stevanato Groupは、正しい科学に基づいたアプローチでリスクの少ない戦略を当初から手抜きをすることなく推進するため、RNA開発者にとって最適なパートナーになっています。

Stevanato Groupは、医薬品バリューチェーン全体をカバーする包括的なソリューションRNA製造プロセスを提供できます
当社は市場における独自の地位を確立しており一次包装、マシン、分析サービスの総合プロバイダーとなることができます。

Stevanato Groupは、当初から手抜きをすることなく単一のインターフェースで適切なソリューションを提供し、市場投入までの時間を短縮するため、RNAテクノロジーに最適なパートナーです。

infographics integrated offering rna based drug
infographics integrated offering rna based drug

当社のソリューション

EZ-fill®キット

臨床段階ですか?EZ-fill®キットがどのように役立つかをご覧ください。

データと結果

当社のEZ-fill® ITCシリンジは、当社が調査した主な課題のすべてのテストに合格しました。以下の結果をご覧ください。

ガラス

Container Closure Integrity (CCI) is maintained at -70°C

Pre-fillable syringes have several components that compose the system, and deep cold storage is a big challenge to maintaining all the materials' integrity.

CCI CHART

Chart: No CO2 was detected in all 30 ITC filled syringes tested through Carbon Dioxide headspace analysis, indicating that no defect allowing CO2 ingress occurred due to any material property changes at -70°C. The controls in both cases performed as expected, showing a substantial ingress of CO2 for the positive control, and no CO2 ingress for the negative controls.

We tested and confirmed no loss of CCI of EZ-fill® ITC syringes after 7 days of storage at -70°C. Tests executed through CO2 Headspace Analysis showed no relevant signals of carbon dioxide ingress after a 1-week freezing cycle whilst also verifying the plunger displacement phenomenon confirming the suitability of EZ-fill® ITC system for mRNA applications.

 

Syringes functionality and closure functionality are not impacted by low temperature of storage.

Low temperature can also affect the functionality of the overall system. Two of the most important parameters that describe the system's functionality are Break Loose and Gliding Force.

Break Loose -40°C

Glide force -40°C

Charts: The test showed that freezing storage has no impact on break loose and gliding force, confirming no functional impact from Room Temperature to -40°C.

We tested - after 1-week storage at -40°C - filled ITC syringes and they showed excellent Break Loose and Gliding Force* performance with comparable results before and after freezing storage.

 

* ISO 11040-4:2015 as a standard reference

ITC unscrewing torque and opening force

We tested the ITC closure unscrew* after 5 cycles at -50° storage with extraordinary results. The test showed no statistical difference in unscrewing torque (Tmax) between the sub-categories, confirming that ITC closure functionality is guaranteed after freezing condition, with no impact on usability for the final user.

Chart: No evidence of difference in unscrewing force for all the 50 ITC syringes tested for each category.

Mechanical properties are not affected after freezing condition storage

Deep cold storage may stress the glass barrel of a PFS system causing potential system failures.

Mechanical resistance

Chart: Results at Room Temperature and at -40°C are comparable, confirming that freezing did not affect glass resistance to breakage.

Regarding mechanical properties, Burst Test* performed on Stevanato Group ITC syringe did not show difference in glass barrel resistance between -40°C and room temperature storage conditions, confirming good mechanical performances.

 

* ISO 7458:2004 as standard reference.

Ensuring CCI at -80°C: Ideal vial solution for pharma cold storage

Market Insight
Covid-19 and the subsequent rise of mRNA vaccines brought new types of therapies to the market that require storage at deep-cold temperatures down to -80 °C.

Risk
The stress on the glass at these low temperatures increases the chance of vial breakage. The risk of breakage is extremely important to pharmaceutical companies due to the high values od drug cointained.

Need
Increased assurance about the compatibility of glass containers with cold storage conditions is key for pharmaceutical companies.

Solution
In this increasingly complex application, EZ-fill® vials are a proven solution to make life easier for customers. Find out Fina® Vial’s optimal performances with deep-cold drug applications and complex cold-chain requirements for both Mechanical & Container Closure Integrity (CCI) performance

Ensuring mechanical resistance with Vertical Compression Test & Burst Test (CTQAs investigated in the study)

Objective
Identify and determine the impact (if any) on glass vials’ mechanical resistance to Axial Load and Internal Pressure of storage conditions of -80°C over a period of 7 days

Method
Vertical Compression and Burst test

Results
2R Fina® quality glass can withstand a conditioning at -80°C for a prolonged period of time without impacting its mechanical performance.

Ensuring Containet Closure Integrity with Headspace Gas Analysis

Objective
Determine CCI during stability at 25°C/60% RH and -80°C at two different time points (T0 and T6 months) over a storage period of 6 months.

Method
Use of Headspace Gas Analysis technique, based on the measurement of the headspace carbon dioxide content in the samples after exposure to a carbon dioxide enriched environment at the target temperatures.

Results
no CO2 detected in all the samples. 2R Fina® vial geometry, in combination with different closure systems, can maintain CCI for a prolonged period of time under the testing conditions

The configurations tested showed no statistically significant difference before and after conditioning.

READ MORE

Mechanical Performances in deep freezing

Mechanical performances scheme

White Paper

mRNA therapies on the rise: Challenges for primary packaging and solutions to test for best performance